

Cancer Populations USA

Squamous-cell carcinoma of the larynx in the United States, 2022-2042

Executive Summary

Date of most recent update: May 24, 2023

Contents

Summary of key findings

Patient Journey Infographic, 2022

National distribution of risk and incident cases, 2022

Contents of the full report

Further information

©Epivantage, 2023. An Epivantage Ltd. publication. Epivantage is a registered trademark of Epivantage Limited with the U.S. Patent and Trademark Office. All data, tabulations and graphics contained herein are copyright Epivantage 2023. Use or citation is at the discretion of Epivantage Ltd and must be sought prior to publication.


Summary of key findings

Nationally, we estimate 11,066 newly diagnosed incident cases of squamous-cell carcinoma of the larynx (SCC-L) in 2022, of which 92% were initially diagnosed at stages of disease amenable to definitive treatment.

We estimate 5,574 advanced 1st line drug-treatable cases nationally in 2022. The majority of these were initially diagnosed with locoregional non-metastatic disease, but subsequently recurred following definitive treatment.

Nationally, the number of incident cases over our 20-year forecast period will fall by 1%.

When considering trends in the risk of SCC-L within each race-ethnicity group, according to our forecast model, the crude incidence rate across the national population will decrease, from an estimated 3.2 per 100,000 per year in 2022 to 2.9 per 100,000 per year in 2042.



Historical and forecast number of incident cases of SCC-L in the United States 2002 to 2042, by race-ethnicity group.


[1] incident cases refers to the number of newly diagnosed incident cases per year; [2] incident cases for mixed race groups is extrapolated from non-mixed racial group estimates within each ethnicity; [3] includes Asian, Pacific Islander, Native American and Alaskan Native race-ethnicity groups.

The age-adjusted risk of SCC-L is highest among black non-Hispanics. The risk of SCC-L is multiple times lower among females than in males.

Patient Journey Infographic, 2022

The figure below depicts - at a high-level - the size of the SCC-L patient population at different points in the patient journey, from having undiagnosed disease, through to diagnosis and staging, and any subsequent recurrence to advanced disease.





© Epivantage Ltd. 2023


Prevalent populations	Drug-treatable populations
Incident populations	Drug-treated populations


[1] age-standardization is to an arbitrary weighting scheme that assigns equal weight to each age group. Standardized estimates to the US 2000 population are available in the main body of the report; [2] we do not estimate the percentage of those eligible for first line treatment that are drug-treated with antineoplastic drugs, and therefore do not report the corresponding number of drug-treated advanced first line cases, although this may be possible as a custom piece of work (along with estimation of later lines of treatment and treatment patterns; contact questions@epivantage.com). "n.r." = not reported.

Legend

National distribution of risk and incident cases, 2022

We estimate that the age-standardized risk of SCC-L is highest in Kentucky at 4.5 per 100,000 person years per year in 2022.






© Epivantage Ltd. 2023

Although Florida does not have the highest age-standardized risk of SCC-L, it is the state with the most newly diagnosed cases in 2022 at 942.

National distribution of incident cases by US state in 2022.



About Epivantage and the Cancer Populations USA report series

Epivantage is an epidemiology consulting, data and insights company. The *Cancer Populations USA* report series provides detailed descriptive epidemiology estimates, forecast out to 20 years, and insights, to support clinical trial design and enrolment, market opportunity assessment and post-marketing authorization activities. For more information please visit www.epivantage.com or email questions@epivantage.com.

Cancer Populations USA is unique in routinely stratifying key cancer populations by race and ethnicity, which can be used to assess the representativeness of clinical trial populations, as well as identify areas of health inequities between different race-ethnicity population groups.

All Epivantage reports can be downloaded via the Epivantage Library for subscribers. While our coverage is extensive, it may not meet everyone's requirements. In those cases where (for example), a different case definition, or an extended forecast, is needed please contact us at questions@epivantage.com to discuss bespoke work or for any questions regarding methods and data sources.

Methods and data sources overview

All estimates in this report are based on nationally representative datasets, such as population-based cancer registries, large epidemiological studies and published national population forecasts. Modeled estimates are based on the best practice industry methods to estimate recurrence events and, where required, make imputations and extrapolations.

Estimates in this report that are stratified by race and ethnicity use slightly broader groupings than those used by the US Census Bureau. This is to allow for sufficiently large samples to generate stable epidemiological estimates. Despite this, some patients counts are too small to be considered reliable. We supress counts less than 5 in most cases, indicating this by "<5".

In addition to using different race-ethnicity groupings than the census, due to inconsistencies in the recording of race and ethnicity between cancer registries and the census, some extrapolations have been made. Specifically, in the case of mixed racial groups - for whom estimates are not routinely reported by population-based cancer registries - the assumption is made that the unreported parameter would be an average of each racial group within each ethnicity.

When referring to those patients that develop disease not amenable to definitive treatment with curative intent in a given year (whether initially diagnosed as such or through disease progression or recurrence following prior definitive treatment), we use the term 'advanced 1st line drug-treatable cases'.

We provide estimates for the year 2022 and forecast estimates to 2032 and 2042 in the main body of this report. Annualized forecast estimates are provided in supplementary tables at the end of the report, and also in the accompanying data dashboard, if purchased.

Stratification of incident cases by stage is based on the scheme specified by the American Joint Committee on Cancer (AJCC) 8th edition (i.e. stage groups I, II, III, IVA, IVB, IVC). Due to small numbers, some stage groups have been aggregated in this report. Wherever possible, this has been into meaningful groupings based on recommended clinical practice (NCCN, 2023).

Chapter headings, tables and figures contained in the full report

Chapter headings

- 1. Introduction
- 2. Summary of results
- 3. Newly diagnosed incident cases
- 4. Advanced 1st line drug-treatable cases
- 5. Tumor genetics and biomarker expression
- 6. State-level epidemiology
- 7. 10 and 20 year epidemiological forecasts
- 8. Detailed methods
- 9. National population projections
- 10. Bibliography
- 11. Supplementary data tables
- 12. Additional support
- 13. Further information

Figures included in the full report

Figure 2.1. Historical and forecast number of incident cases of SCC-L in the United States 2002 to 2042, by raceethnicity group.

Figure 2.2. Heat map of state-specific risk of SCC-L by US state in 2022.

Figure 2.3. Patient journey of SCC-L patients in the United States, 2022.

Figure 6.1. Heat map of state-specific risk of SCC-L by US state in 2022.

Figure 6.2. Heat map of the number of SCC-L incident cases by US state in 2022.

Figure 7.1. Historical trends in crude incidence of SCC-L with forecast to 2042 by race-ethnicity group.

Figure 8.1. Historical trends in age-standardized incidence of SCC-L with forecast to 2042 by race-ethnicity.

Figure 9.1. Racial and ethnic composition of the United States population in 2022 and 2042.

Figure 9.2. Changes in the proportion of the population within each race-ethnicity group that is aged 65 or over in 2022 and 2042.

Figure 9.3. Changes in the proportion of the population within each race-ethnicity group that is aged under 20 in 2022 and 2042.

Tables (excluding those in the accompanying data dashboard)

Table 2.1. Summary incidence and survival of SCC-L by race-ethnicity group in 2022.

Table 3.1. Newly diagnosed incident cases and incidence of SCC-L by sex and race-ethnicity in 2022.

Table 3.2. Newly diagnosed incident cases of SCC-L by stage at diagnosis and race-ethnicity.

Table 3.3. Stage distribution of SCC-L incident cases by race-ethnicity in 2022.

Table 3.4. Incident cases of SCC-L by broad age group and stage at diagnosis in 2022.

Table 3.5. Percentage distribution of incident cases of SCC-L by broad age group and stage at diagnosis in 2022.

Table 3.6. Newly diagnosed incident cases of SCC-L and Stage IVB/C incident cases by broad age group at diagnosis in 2022.

Table 3.7. Incidence and incident cases of SCC-L by sex in 2022.

Table 3.8. Newly diagnosed incident cases of SCC-L by anatomical tumor subsite in 2022.

Table 3.9. Incident cases of SCC-L by stage at diagnosis and histology in 2022.

Tables (continued)

Table 4.1. Advanced 1st line drug-treatable cases (1L DTCs) in 2022 and estimated annualized advanced disease risk of SCC-L by race-ethnicity.

Table 4.2. Oberved survival of incident Stage IVB/C SCC-L by race-ethnicity.

Table 4.3. Advanced 1st line drug-treatable cases of SCC-L alive at subsequent follow-up points, by race-ethnicity.

Table 5.1. Significant mutations and corresponding number of advanced 1st line drug-treatable cases of SCC-L in 2022, 2032 and 2042.

Table 5.2. Significant gene amplifications and corresponding number of advanced 1st line drug-treatable cases of SCC-L in 2022, 2032 and 2042.

Table 5.3. PD-L1 positive incident cases of SCC-L in 2022, 2032 and 2042.

Table 6.1. Top ten US states and Puerto Rico ranked by incidence of SCC-L in 2022 and associated cases.

Table 6.2. Top ten US states and Puerto Rico ranked by number of advanced 1st line drug-treatable cases of SCC-L in 2022 and associated incidence and incident cases.

Table 7.1. Incident cases of SCC-L by demographic and tumor characteristics at diagnosis forecast for the years 2022, 2032 and 2042.

Table 7.2. Advanced 1st line drug-treatable cases (1L DTCs) of SCC-L by demographic characteristics at diagnosis and recurrence status forecast for the years 2022, 2032 and 2042.

Table 9.1. Population projections by race-ethnicity group in 2022 and 2042 for all ages and for those aged 65 or over over the forecast period.

Table 11.1. US states and Puerto Rico ranked by incidence of SCC-L in 2022 and associated cases.

Table 11.2. US states and Puerto Rico ranked by number of advanced 1st line drug-treatable cases of SCC-L in 2022 and associated incidence and incident cases.

Table 11.4. Annualized 20-year forecast of incident cases of SCC-L by stage at diagnosis.

Further information

Epivantage reports and the underlying methods have been designed by Dr Mike Hughes, an epidemiologist with many years' experience in the development of epidemiological forecast models for the pharmaceutical industry. While we focus on cancer indications, comparable reports can be produced for any indication subject to availability of reliable data.

In addition to our syndicated report series, we are also able to provide consulting input into the development of custom epidemiological forecast models, selection of real world evidence (RWE) data sources for the comissioning of custom studies, the design of RWE study protocols, and support the execution of statistical analysis plans.

Our Cancer Populations USA report series covers numerous cancer indications, and can be requested on-demand for any tumor not already covered. Those tumors currently covered are listed below by tumor site. Please email questions@epivantage.com to discuss additional coverage.

CNS, respiratory and head and neck

Astrocytoma and glioblastoma Large-cell and other lung cancer Larynx cancer Lung adenocarcinoma Mesothelioma Non-small-cell lung cancer Non-squamous non-small-cell lung cancer Squamous-cell carcinoma of the pharynx and oral cavity Small-cell-lung cancer Squamous-cell carcinoma of the head and neck Squamous-cell carcinoma of the larynx Squamous-cell carcinoma of the oral cavity Squamous-cell carcinoma of the pharynx and overlapping areas

Digestive and endocrine

Adenocarcinoma of the Biliary tract cancer Cholangiocarcinoma Colon cancer Colorectal cancer Esophageal cancer Exocrine pancreatic cancer Gastric adenocarcinoma Gastroesophageal Gastroesophageal cancer Hepatocellular carcinoma Liver and biliary tract cancer Rectal cancer Differentiated thyroid cancer Neuroendocrine tumours

Epi**v**antage

Reproductive and genito-urinary

Bladder cancer Breast cancer (all subtypes) Cervical cancer Endometrial cancer HER2 positive breast cancer (HR positive or negative) HR negative, HER2 positive breast cancer HR positive breast cancer (HER2 positive or negative) HR positive, HER2 negative breast cancer HR positive, HER2 positive breast cancer Non-metastatic prostate cancer Non-muscle-invasive bladder cancer Ovarian cancer Prostate cancer Renal-cell carcinoma Squamous-cell carcinoma of the esophagus Triple negative breast cancer

Hematological and lymphatic

Acute lymphoblastic leukemia Acute myeloid leukemia Acute myeloid leukemia and high-risk myelodysplastic syndromes B-cell non-Hodgkin's lymphoma Chronic myeloid leukemia Diffuse large B-cell lymphoma Follicular lymphoma Hodgkin's lymphoma Mantle-cell lymphoma Mucosa-associated lymphoid tissue lymphoma Multiple myeloma Myelodysplastic syndromes **Myelofibrosis** Non-Hodgkin's lymphoma Small-cell B-cell lymphoma and B-cell chronic lymphocytic leukemia T-cell non-Hodgkin's lymphoma

Other

Malignant melanoma